Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark : baseline results from the non-interventional multicentre AWARE study. / Thomsen, S. F.; Pritzier, E. C.; Anderson, C. D.; Vaugelade-Baust, N.; Dodge, R.; Dahlborn, A. K.; Vestergaard, C.

I: Journal of the European Academy of Dermatology and Venereology, Bind 31, Nr. 6, 2017, s. 1048-1055.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Thomsen, SF, Pritzier, EC, Anderson, CD, Vaugelade-Baust, N, Dodge, R, Dahlborn, AK & Vestergaard, C 2017, 'Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study', Journal of the European Academy of Dermatology and Venereology, bind 31, nr. 6, s. 1048-1055. https://doi.org/10.1111/jdv.14210

APA

Thomsen, S. F., Pritzier, E. C., Anderson, C. D., Vaugelade-Baust, N., Dodge, R., Dahlborn, A. K., & Vestergaard, C. (2017). Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. Journal of the European Academy of Dermatology and Venereology, 31(6), 1048-1055. https://doi.org/10.1111/jdv.14210

Vancouver

Thomsen SF, Pritzier EC, Anderson CD, Vaugelade-Baust N, Dodge R, Dahlborn AK o.a. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. Journal of the European Academy of Dermatology and Venereology. 2017;31(6):1048-1055. https://doi.org/10.1111/jdv.14210

Author

Thomsen, S. F. ; Pritzier, E. C. ; Anderson, C. D. ; Vaugelade-Baust, N. ; Dodge, R. ; Dahlborn, A. K. ; Vestergaard, C. / Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark : baseline results from the non-interventional multicentre AWARE study. I: Journal of the European Academy of Dermatology and Venereology. 2017 ; Bind 31, Nr. 6. s. 1048-1055.

Bibtex

@article{7b00c69b414447b4bf528f1edba1b32e,
title = "Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study",
abstract = "Background: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. Objective: To examine baseline data from Scandinavian AWARE patients. Methods: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. Results: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2, respectively. The majority of patients were female (69.6{\%}), had uncontrolled CU (75.6{\%}; UCT score <12) and had a ‘spontaneous’ component to their CU (61.4{\%} CSU; 20.3{\%} both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6{\%}), allergic rhinitis (16.5{\%}) and food allergies (8.2{\%}). Overall, 60.1{\%} of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5{\%}), corticosteroids (19{\%}), montelukast (14.6{\%}) and omalizumab (8.2{\%}). Pharmacological treatment rates increased to 96.2{\%} during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. Conclusion: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100{\%} during the baseline visit.",
author = "Thomsen, {S. F.} and Pritzier, {E. C.} and Anderson, {C. D.} and N. Vaugelade-Baust and R. Dodge and Dahlborn, {A. K.} and C. Vestergaard",
year = "2017",
doi = "10.1111/jdv.14210",
language = "English",
volume = "31",
pages = "1048--1055",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark

T2 - baseline results from the non-interventional multicentre AWARE study

AU - Thomsen, S. F.

AU - Pritzier, E. C.

AU - Anderson, C. D.

AU - Vaugelade-Baust, N.

AU - Dodge, R.

AU - Dahlborn, A. K.

AU - Vestergaard, C.

PY - 2017

Y1 - 2017

N2 - Background: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. Objective: To examine baseline data from Scandinavian AWARE patients. Methods: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. Results: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2, respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score <12) and had a ‘spontaneous’ component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. Conclusion: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.

AB - Background: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. Objective: To examine baseline data from Scandinavian AWARE patients. Methods: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. Results: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2, respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score <12) and had a ‘spontaneous’ component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. Conclusion: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.

U2 - 10.1111/jdv.14210

DO - 10.1111/jdv.14210

M3 - Journal article

C2 - 28294420

AN - SCOPUS:85017141219

VL - 31

SP - 1048

EP - 1055

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 6

ER -

ID: 196916908